Evidence map›Paper›PMID 34199761›Full record

ReviewVaccines2021

The Many Faces of Innate Immunity in SARS-CoV-2 Infection.

Nicholas Hanan, Ronnie L Doud, In-Woo Park, Harlan P Jones, Stephen O Mathew

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nicholas HananGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-8005-1291
Ronnie L DoudGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
In-Woo ParkGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Harlan P JonesGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Stephen O MathewGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0001-5784-224X
University of North Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innate immune system is important for initial antiviral response. SARS-CoV-2 can result in overactivity or suppression of the innate immune system. A dysregulated immune response is associated with poor outcomes; with patients having significant Neutrophil-to-Lymphocyte ratios (NLR) due to neutrophilia alongside lymphopenia. Elevated interleukin (IL)-6 and IL-8 leads to overactivity and is a prominent feature of severe COVID-19 patients. IL-6 can result in lymphopenia; where COVID-19 patients typically have significantly altered lymphocyte subsets. IL-8 attracts neutrophils; which may play a significant role in lung tissue damage with the formation of neutrophil extracellular traps leading to cytokine storm or acute respiratory distress syndrome. Several factors like pre-existing co-morbidities, genetic risks, viral pathogenicity, and therapeutic efficacy act as important modifiers of SARS-CoV-2 risks for disease through an interplay with innate host inflammatory responses. In this review, we discuss the role of the innate immune system at play with other important modifiers in SARS-CoV-2 infection.

Indexed as

COVID-19cytokinesinnate immunitySARS-CoV-2

Identifiers

PMID34199761
PMCPMC8228170
OpenAlexW3168815991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.